Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Amplifica General Information
First-in-human clinical trial of AMP-303 demonstrated safety and promising efficacy, with over 15% increase in thicker/coarser hair at day 60 post-treatment in men aged 18–45 with androgenetic alopecia. Results were presented at major dermatology meetings and published in peer-reviewed journals. Additional programs are preclinical.
Contact Information
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Exclusive licensing agreement for early-stage protein asset to expand pipeline
Amplifica Funding
No funding data available
To view Amplifica's complete valuation and funding history, request access »